JP6619650B2 - 新規のｐｃｓｋ９結合タンパク質 - Google Patents

新規のｐｃｓｋ９結合タンパク質 Download PDF

Info

Publication number
JP6619650B2
JP6619650B2 JP2015562159A JP2015562159A JP6619650B2 JP 6619650 B2 JP6619650 B2 JP 6619650B2 JP 2015562159 A JP2015562159 A JP 2015562159A JP 2015562159 A JP2015562159 A JP 2015562159A JP 6619650 B2 JP6619650 B2 JP 6619650B2
Authority
JP
Japan
Prior art keywords
pcsk9
seq
mutein
glu
asp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015562159A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016519051A (ja
JP2016519051A5 (enExample
Inventor
ガブリエレ マチナー
ガブリエレ マチナー
クリスティン ローテ
クリスティン ローテ
アンドレアス ホールバウム
アンドレアス ホールバウム
アイバ ラチダ シハム ベル
アイバ ラチダ シハム ベル
マーロン ヒンナー
マーロン ヒンナー
アンドレア アレルスドーファー
アンドレア アレルスドーファー
ブラッドリー ルンデ
ブラッドリー ルンデ
アレクサンダー ウィーデンマン
アレクサンダー ウィーデンマン
山口　真司
真司 山口
隆秀 油谷
隆秀 油谷
隆二 橋本
隆二 橋本
高橋　亘
亘 高橋
智香子 長崎
智香子 長崎
奈良　太
太 奈良
友宏 西澤
友宏 西澤
Original Assignee
ピエリス ファーマシューティカルズ ゲーエムベーハー
ピエリス ファーマシューティカルズ ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ピエリス ファーマシューティカルズ ゲーエムベーハー, ピエリス ファーマシューティカルズ ゲーエムベーハー filed Critical ピエリス ファーマシューティカルズ ゲーエムベーハー
Publication of JP2016519051A publication Critical patent/JP2016519051A/ja
Publication of JP2016519051A5 publication Critical patent/JP2016519051A5/ja
Application granted granted Critical
Publication of JP6619650B2 publication Critical patent/JP6619650B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
JP2015562159A 2013-03-14 2014-03-13 新規のｐｃｓｋ９結合タンパク質 Expired - Fee Related JP6619650B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361781511P 2013-03-14 2013-03-14
US61/781,511 2013-03-14
EP13175023 2013-07-04
EP13175023.4 2013-07-04
PCT/EP2014/055013 WO2014140210A1 (en) 2013-03-14 2014-03-13 Novel binding proteins for pcsk9

Publications (3)

Publication Number Publication Date
JP2016519051A JP2016519051A (ja) 2016-06-30
JP2016519051A5 JP2016519051A5 (enExample) 2017-04-13
JP6619650B2 true JP6619650B2 (ja) 2019-12-11

Family

ID=48703321

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015562159A Expired - Fee Related JP6619650B2 (ja) 2013-03-14 2014-03-13 新規のｐｃｓｋ９結合タンパク質

Country Status (15)

Country Link
US (3) US9150629B2 (enExample)
EP (1) EP2968490A1 (enExample)
JP (1) JP6619650B2 (enExample)
KR (1) KR20150131151A (enExample)
CN (1) CN105246503A (enExample)
AU (1) AU2014230460B2 (enExample)
BR (1) BR112015021681A2 (enExample)
CA (1) CA2905186A1 (enExample)
HK (1) HK1213194A1 (enExample)
IL (1) IL241329A0 (enExample)
MX (1) MX2015012420A (enExample)
PH (1) PH12015501687A1 (enExample)
RU (1) RU2015142437A (enExample)
SG (1) SG11201505856TA (enExample)
WO (1) WO2014140210A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
BR112015021681A2 (pt) 2013-03-14 2017-11-14 Daiichi Sankyo Co Ltd proteínas de ligação para pcsk9
WO2015095553A1 (en) * 2013-12-20 2015-06-25 Nephrogenesis, Llc Methods and apparatus for kidney dialysis
US9398085B2 (en) 2014-11-07 2016-07-19 Ringcentral, Inc. Systems and methods for initiating a peer-to-peer communication session
CA2980839C (en) 2015-05-04 2024-09-10 Pieris Pharmaceuticals Gmbh CD137 SPECIFIC PROTEINS
WO2019222529A1 (en) 2018-05-16 2019-11-21 Lib Therapeutics, Llc Compositions comprising pcsk9-binding molecules and methods of use
EP3810176B1 (en) 2018-06-21 2024-12-11 Ra Pharmaceuticals, Inc. Cyclic polypeptides for pcsk9 inhibition
US11814445B2 (en) 2018-06-21 2023-11-14 Ra Pharmaceuticals, Inc. Cyclic polypeptides for PCSK9 inhibition
JOP20190150A1 (ar) * 2018-06-21 2019-12-21 Merck Sharp & Dohme مركبات مناهضة لـ pcsk9
BR112021013807A2 (pt) 2019-01-18 2021-11-30 Astrazeneca Ab Inibidores de pcsk9 e seus métodos de uso
AU2020253034A1 (en) * 2019-03-29 2021-08-19 Pieris Pharmaceuticals Gmbh Inhaled administration of lipocalin muteins
WO2022021000A1 (zh) * 2020-07-27 2022-02-03 深圳华大生命科学研究院 一种抗体结合的特征性表位及其应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
DE4417598A1 (de) 1994-05-19 1995-12-14 Max Planck Gesellschaft Verwendung des Tetracyclinpromotors zur stringent regulierten Produktion von rekombinanten Proteinen in prokaryontischen Zellen
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2233725A1 (en) 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes
TR200003635T2 (tr) 1998-06-08 2001-04-20 F.Hoffmann-La Roche Ag Peg-IFN-ALFA ve ribavirinin kronik hepatit C tedavisinde kullanılması.
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
DE19926068C1 (de) 1999-06-08 2001-01-11 Arne Skerra Muteine des Bilin-Bindungsproteins
JP4336771B2 (ja) 2001-03-09 2009-09-30 モルフォシス アーゲー 血清アルブミン結合部分
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
US7118915B2 (en) 2001-09-27 2006-10-10 Pieris Proteolab Ag Muteins of apolipoprotein D
AT411852B (de) 2002-02-12 2004-06-25 Didosyan Yuri S Dr Verfahren und vorrichtung zur änderung des polarisationszustandes von licht mit einem magnetisch einachsigen kristall
AU2003264100A1 (en) 2003-08-25 2005-03-10 Pieris Proteolab Ag Muteins of a bilin-binding protein with affinity for a given target
AU2003275958A1 (en) 2003-08-25 2005-03-10 Pieris Proteolab Ag Muteins of tear lipocalin
EP2899277A1 (en) 2004-11-26 2015-07-29 Pieris AG Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
US20070191272A1 (en) 2005-09-27 2007-08-16 Stemmer Willem P Proteinaceous pharmaceuticals and uses thereof
EP1996613B1 (en) * 2006-03-20 2014-04-30 Technische Universität München Muteins of tear lipocalin with affinity for the t-cell coreceptor cd4
JP5608368B2 (ja) * 2006-08-01 2014-10-15 ピエリス アーゲー 涙リポカリンの突然変異タンパク質およびそれを得るための方法
CA2668131A1 (en) * 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonists of pcsk9
CN101636179B (zh) * 2006-11-07 2012-10-10 默沙东公司 Pcsk9拮抗剂
EP2137218A2 (en) * 2007-04-13 2009-12-30 Novartis Ag Molecules and methods for modulating proprotein convertase subtilisin/kexin type 9 (pcsk9)
EP2190863B1 (en) 2007-07-31 2015-09-02 Affibody AB New albumin binding compositions, methods and uses
TR201906295T4 (tr) * 2010-06-08 2019-05-21 Astrazeneca Ab IL-4 R alfaya bağlanan gözyaşı lipokalini muteinleri.
JP5827994B2 (ja) 2010-07-09 2015-12-02 アフィボディ・アーベー ポリペプチド
WO2013104586A1 (en) * 2012-01-09 2013-07-18 Pieris Ag Methods for preventing, treating or diagnosing disorders
BR112015021681A2 (pt) 2013-03-14 2017-11-14 Daiichi Sankyo Co Ltd proteínas de ligação para pcsk9

Also Published As

Publication number Publication date
BR112015021681A2 (pt) 2017-11-14
WO2014140210A1 (en) 2014-09-18
MX2015012420A (es) 2016-06-02
US9150629B2 (en) 2015-10-06
EP2968490A1 (en) 2016-01-20
CA2905186A1 (en) 2014-09-18
SG11201505856TA (en) 2015-08-28
CN105246503A (zh) 2016-01-13
US20140288008A1 (en) 2014-09-25
RU2015142437A (ru) 2017-04-27
HK1213194A1 (zh) 2016-06-30
US20170173112A1 (en) 2017-06-22
JP2016519051A (ja) 2016-06-30
AU2014230460B2 (en) 2018-04-05
AU2014230460A1 (en) 2015-09-10
KR20150131151A (ko) 2015-11-24
US9598476B2 (en) 2017-03-21
US20160024161A1 (en) 2016-01-28
PH12015501687A1 (en) 2015-10-19
IL241329A0 (en) 2015-11-30

Similar Documents

Publication Publication Date Title
JP6619650B2 (ja) 新規のｐｃｓｋ９結合タンパク質
JP5902679B2 (ja) ＩＬ−４Ｒαに結合する涙液リポカリンムテイン
JP6486908B2 (ja) 肝細胞増殖因子に結合する設計アンキリン反復タンパク質
TW201524994A (zh) Ｐｃｓｋ９新穎結合蛋白
HK1232549A1 (en) Tear lipocalin muteins binding il-4 r alpha
HK1232549B (zh) 结合IL-4受体α的泪脂质运载蛋白突变蛋白
HK40034619A (en) Tear lipocalin muteins binding il-4 r alpha

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170309

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170309

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180228

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180410

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20180509

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180509

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180727

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190528

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190930

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191002

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20191017

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191115

R150 Certificate of patent or registration of utility model

Ref document number: 6619650

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees